{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:08:26Z","timestamp":1774926506467,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1245\/s10434-024-16822-4","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T18:31:37Z","timestamp":1737052297000},"page":"2425-2434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Associations of KRAS Point Mutations with Survival of Patients Who Underwent Curative-Intent Resection of Colorectal Liver Metastases"],"prefix":"10.1245","volume":"32","author":[{"given":"Harufumi","family":"Maki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reed I.","family":"Ayabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antony","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujiro","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy E.","family":"Newhook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hop S.","family":"Tran Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Shin","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Wei D.","family":"Tzeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Nicolas","family":"Vauthey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"16822_CR1","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jamasurg.2015.0313","volume":"150","author":"GA Margonis","year":"2015","unstructured":"Margonis GA, Kim Y, Spolverato G, et al. Association between specific mutations in KRAS codon 12 and colorectal liver metastasis. JAMA Surg. 2015;150:722\u20139.","journal-title":"JAMA Surg."},{"key":"16822_CR2","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/bjs\/znab086","volume":"108","author":"Y Kawaguchi","year":"2021","unstructured":"Kawaguchi Y, Kopetz S, Tran Cao HS, et al. Contour prognostic model for predicting survival after resection of colorectal liver metastases: development and multicentre validation study using largest diameter and number of metastases with RAS mutation status. Br J Surg. 2021;108:968.","journal-title":"Br J Surg."},{"key":"16822_CR3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/SLA.0000000000002450","volume":"269","author":"YS Chun","year":"2019","unstructured":"Chun YS, Passot G, Yamashita S, et al. Deleterious effect of RAS and evolutionary high-risk TP53 double mutation in colorectal liver metastases. Ann Surg. 2019;269:917\u201323.","journal-title":"Ann Surg."},{"issue":"272\u2013284","key":"16822_CR4","first-page":"e213","volume":"233","author":"Y Kawaguchi","year":"2021","unstructured":"Kawaguchi Y, Kopetz S, Kwong L, et al. Genomic sequencing and insight into clinical heterogeneity and prognostic pathway genes in patients with metastatic colorectal cancer. J Am Coll Surg. 2021;233(272\u2013284):e213.","journal-title":"J Am Coll Surg."},{"key":"16822_CR5","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/bjs.9870","volume":"102","author":"KW Brudvik","year":"2015","unstructured":"Brudvik KW, Kopetz SE, Li L, Conrad C, Aloia TA, Vauthey JN. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg. 2015;102:1175\u201383.","journal-title":"Br J Surg."},{"key":"16822_CR6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/SLA.0b013e3182a5025a","volume":"258","author":"JN Vauthey","year":"2013","unstructured":"Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258:619\u201326.","journal-title":"Ann Surg."},{"key":"16822_CR7","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/SLA.0000000000002319","volume":"269","author":"KW Brudvik","year":"2019","unstructured":"Brudvik KW, Jones RP, Giuliante F, et al. RAS mutation clinical risk score to predict survival after resection of colorectal liver metastases. Ann Surg. 2019;269:120\u20136.","journal-title":"Ann Surg."},{"key":"16822_CR8","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1158\/1078-0432.CCR-19-0863","volume":"25","author":"Y Kawaguchi","year":"2019","unstructured":"Kawaguchi Y, Kopetz S, Newhook TE, et al. Mutation status of RAS, TP53, and SMAD4 is superior to mutation status of RAS alone for predicting prognosis after resection of colorectal liver metastases. Clin Cancer Res. 2019;25:5843\u201351.","journal-title":"Clin Cancer Res."},{"key":"16822_CR9","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1158\/1078-0432.CCR-19-2390","volume":"26","author":"J Datta","year":"2020","unstructured":"Datta J, Smith JJ, Chatila WK, et al. Coaltered RAS\/B-raf and TP53 Is associated with extremes of survivorship and distinct patterns of metastasis in patients with metastatic colorectal cancer. Clin Cancer Res. 2020;26:1077\u201385.","journal-title":"Clin Cancer Res."},{"key":"16822_CR10","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.3390\/cancers14143320","volume":"14","author":"A Koulouridi","year":"2022","unstructured":"Koulouridi A, Karagianni M, Messaritakis I, et al. Prognostic value of KRAS mutations in colorectal cancer patients. Cancers Basel. 2022;14:3320.","journal-title":"Cancers Basel"},{"key":"16822_CR11","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/jnci\/90.9.675","volume":"90","author":"HJ Andreyev","year":"1998","unstructured":"Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten RAS mutations in patients with colorectal cancer: the multicenter RASCAL\u201d study. J Natl Cancer Inst. 1998;90:675\u201384.","journal-title":"J Natl Cancer Inst."},{"key":"16822_CR12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1054\/bjoc.2001.1964","volume":"85","author":"HJ Andreyev","year":"2001","unstructured":"Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten RAS mutations in patients with colorectal cancer: the \u201cRASCAL II\u201d study. Br J Cancer. 2001;85:692\u20136.","journal-title":"Br J Cancer."},{"key":"16822_CR13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/cncr.30351","volume":"123","author":"TL Frankel","year":"2017","unstructured":"Frankel TL, Vakiani E, Nathan H, et al. Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. Cancer. 2017;123:568\u201375.","journal-title":"Cancer."},{"key":"16822_CR14","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.surg.2016.07.032","volume":"161","author":"G Passot","year":"2017","unstructured":"Passot G, Denbo JW, Yamashita S, et al. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. Surgery. 2017;161:332\u201340.","journal-title":"Surgery."},{"key":"16822_CR15","first-page":"153303382110391","volume":"20","author":"Z Lin","year":"2021","unstructured":"Lin Z, Liu Y, Cai S, Yang C, Zhou L, Li W. Not all Kirsten rat sarcoma viral oncogene homolog mutations predict poor survival in patients with unresectable colorectal liver metastasis. Technol Cancer Res Treat. 2021;20:15330338211039132.","journal-title":"Technol Cancer Res Treat."},{"key":"16822_CR16","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1245\/s10434-020-08862-3","volume":"28","author":"LV Saadat","year":"2021","unstructured":"Saadat LV, Boerner T, Goldman DA, et al. Association of RAS mutation location and oncologic outcomes after resection of colorectal liver metastases. Ann Surg Oncol. 2021;28:817\u201325.","journal-title":"Ann Surg Oncol."},{"key":"16822_CR17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11523-021-00856-9","volume":"17","author":"A Alawawdeh","year":"2022","unstructured":"Alawawdeh A, Piantadosi C, Townsend AR, et al. Prognostic differences of RAS mutations: results from the South Australian metastatic colorectal registry. Target Oncol. 2022;17:35\u201341.","journal-title":"Target Oncol."},{"key":"16822_CR18","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/bjs\/znac147","volume":"109","author":"PB Olthof","year":"2022","unstructured":"Olthof PB, Buettner S, Andreatos N, et al. KRAS alterations in colorectal liver metastases: shifting to exon, codon, and point mutations. Br J Surg. 2022;109:804\u20137.","journal-title":"Br J Surg."},{"key":"16822_CR19","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.18632\/oncotarget.13697","volume":"8","author":"S Renaud","year":"2017","unstructured":"Renaud S, Guerrera F, Seitlinger J, et al. KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer. Oncotarget. 2017;8:2514\u201324.","journal-title":"Oncotarget."},{"key":"16822_CR20","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ags3.12591","volume":"6","author":"GA Margonis","year":"2022","unstructured":"Margonis GA, Vauthey JN. Precision surgery for colorectal liver metastases: current knowledge and future perspectives. Ann Gastroenterol Surg. 2022;6:606\u201315.","journal-title":"Ann Gastroenterol Surg."},{"key":"16822_CR21","volume-title":"AJCC cancer staging manual","author":"MB Amin","year":"2018","unstructured":"Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual. 8th edn. Chicago, IL: Springer International Publishing AG; 2018.","edition":"8"},{"key":"16822_CR22","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1001\/jama.2009.1755","volume":"302","author":"YS Chun","year":"2009","unstructured":"Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302:2338\u201344.","journal-title":"JAMA"},{"key":"16822_CR23","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jamcollsurg.2010.02.039","volume":"210","author":"A Brouquet","year":"2010","unstructured":"Brouquet A, Mortenson MM, Vauthey JN, et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg. 2010;210:934\u201341.","journal-title":"J Am Coll Surg."},{"key":"16822_CR24","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-16370-x","author":"A Haddad","year":"2024","unstructured":"Haddad A, Lendoire M, Uppal A, et al. CEA rebound after discontinuation of pre-hepatectomy chemotherapy predicts worse outcomes after resection of colorectal cancer liver metastases. Ann Surg Oncol. 2024. https:\/\/doi.org\/10.1245\/s10434-024-16370-x.","journal-title":"Ann Surg Oncol."},{"key":"16822_CR25","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/S1470-2045(24)00039-1","volume":"25","author":"A Haddad","year":"2024","unstructured":"Haddad A, Lendoire M, Paolucci I, Kang HC, Vauthey JN. Optimal imaging before local therapy of colorectal liver metastases. Lancet Oncol. 2024;25:e99.","journal-title":"Lancet Oncol."},{"key":"16822_CR26","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/ags3.12689","volume":"7","author":"H Maki","year":"2023","unstructured":"Maki H, Jain AJ, Haddad A, Lendoire M, Chun YS, Vauthey JN. Locoregional treatment for colorectal liver metastases aiming for precision medicine. Ann Gastroenterol Surg. 2023;7:543\u201352.","journal-title":"Ann Gastroenterol Surg."},{"key":"16822_CR27","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-16558-1","author":"A Haddad","year":"2024","unstructured":"Haddad A, Khavandi MM, Lendoire M, et al. Propensity score-matched analysis of liver venous deprivation and portal vein embolization before planned hepatectomy in patients with extensive colorectal liver metastases and high-risk factors for inadequate regeneration. Ann Surg Oncol. 2024. https:\/\/doi.org\/10.1245\/s10434-024-16558-1.","journal-title":"Ann Surg Oncol."},{"key":"16822_CR28","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.gassur.2024.02.020","volume":"28","author":"A Haddad","year":"2024","unstructured":"Haddad A, Lendoire M, Maki H, et al. Liver volumetry and liver-regenerative interventions: history, rationale, and emerging tools. J Gastrointest Surg. 2024;28:766.","journal-title":"J Gastrointest Surg."},{"key":"16822_CR29","doi-asserted-by":"crossref","first-page":"e000262","DOI":"10.1136\/fmch-2019-000262","volume":"8","author":"MZI Chowdhury","year":"2020","unstructured":"Chowdhury MZI, Turin TC. Variable selection strategies and its importance in clinical prediction modelling. Fam Med Commun Health. 2020;8:e000262.","journal-title":"Fam Med Commun Health"},{"key":"16822_CR30","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/aje\/kwk052","volume":"165","author":"E Vittinghoff","year":"2007","unstructured":"Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165:710\u20138.","journal-title":"Am J Epidemiol."},{"key":"16822_CR31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0092-8674(00)00123-9","volume":"103","author":"S Ries","year":"2000","unstructured":"Ries S, Biederer C, Woods D, et al. Opposing effects of RAS on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell. 2000;103:321\u201330.","journal-title":"Cell"},{"issue":"5813","key":"16822_CR32","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1126\/science.1135961","volume":"315","author":"M Cordenonsi","year":"2007","unstructured":"Cordenonsi M, Montagner M, Adorno M, et al. Integration of TGF-beta and RAS\/MAPK signaling through p53 phosphorylation. Science. 2007;315(5813):840\u20133.","journal-title":"Science"},{"key":"16822_CR33","doi-asserted-by":"crossref","first-page":"111972","DOI":"10.1016\/j.celrep.2022.111972","volume":"42","author":"X Wang","year":"2023","unstructured":"Wang X, Xie Q, Ji Y, et al. Targeting KRAS-mutant stomach\/colorectal tumors by disrupting the ERK2-p53 complex. Cell Rep. 2023;42:111972.","journal-title":"Cell Rep."},{"key":"16822_CR34","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1158\/2159-8290.CD-20-1228","volume":"11","author":"MP Kim","year":"2021","unstructured":"Kim MP, Li X, Deng J, et al. Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis. Cancer Discov. 2021;11:2094\u2013111.","journal-title":"Cancer Discov."},{"key":"16822_CR35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/SLA.0000000000004672","volume":"276","author":"HA Lillemoe","year":"2020","unstructured":"Lillemoe HA, Passot G, Kawaguchi Y, et al. RAS\/TP53 Co-mutation is associated with worse survival after concurrent resection of colorectal liver metastases and extrahepatic disease. Ann Surg. 2020;276:357.","journal-title":"Ann Surg."},{"key":"16822_CR36","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/XCS.0000000000000093","volume":"234","author":"Y Nishioka","year":"2022","unstructured":"Nishioka Y, Chun YS, Overman MJ, et al. Effect of co-mutation of RAS and TP53 on postoperative ctDNA detection and early recurrence after hepatectomy for colorectal liver metastases. J Am Coll Surg. 2022;234:474\u201383.","journal-title":"J Am Coll Surg."},{"key":"16822_CR37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/XCS.0000000000000223","volume":"235","author":"YS Chun","year":"2022","unstructured":"Chun YS, Passot G, Nishioka Y, et al. Colorectal liver micrometastases: association with RAS\/TP53 co-mutation and prognosis after surgery. J Am Coll Surg. 2022;235:8\u201316.","journal-title":"J Am Coll Surg."},{"key":"16822_CR38","doi-asserted-by":"crossref","first-page":"7093","DOI":"10.1021\/bi5011333","volume":"53","author":"MG Khrenova","year":"2014","unstructured":"Khrenova MG, Mironov VA, Grigorenko BL, Nemukhin AV. Modeling the role of G12V and G13V RAS mutations in the RAS-GAP-catalyzed hydrolysis reaction of guanosine triphosphate. Biochemistry. 2014;53:7093\u20139.","journal-title":"Biochemistry."},{"key":"16822_CR39","doi-asserted-by":"crossref","first-page":"21949","DOI":"10.1038\/srep21949","volume":"6","author":"S Lu","year":"2016","unstructured":"Lu S, Jang H, Nussinov R, Zhang J. The Structural basis of oncogenic mutations G12, G13, and Q61 in small GTPase K-RAS4B. Sci Rep. 2016;6:21949.","journal-title":"Sci Rep."},{"key":"16822_CR40","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/s41467-022-29061-6","volume":"13","author":"Y Haraoka","year":"2022","unstructured":"Haraoka Y, Akieda Y, Nagai Y, Mogi C, Ishitani T. Zebrafish imaging reveals TP53 mutation switching oncogene-induced senescence from suppressor to driver in primary tumorigenesis. Nat Commun. 2022;13:1417.","journal-title":"Nat Commun."},{"key":"16822_CR41","doi-asserted-by":"crossref","first-page":"e73616","DOI":"10.1371\/journal.pone.0073616","volume":"8","author":"S Petanidis","year":"2013","unstructured":"Petanidis S, Anestakis D, Argyraki M, Hadzopoulou-Cladaras M, Salifoglou A. Differential expression of IL-17, 22, and 23 in the progression of colorectal cancer in patients with K-RAS mutation: RAS signal inhibition and crosstalk with GM-CSF and IFN-gamma. PLoS One. 2013;8:e73616.","journal-title":"PLoS One."},{"key":"16822_CR42","first-page":"53","volume":"13","author":"M Michel","year":"2021","unstructured":"Michel M, Kaps L, Maderer A, Galle PR, Moehler M. The role of dysfunction in colorectal cancer and its implication for therapy. Cancers Basel. 2021;13:53.","journal-title":"Cancers Basel"},{"key":"16822_CR43","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/cbin.11524","volume":"45","author":"LN Pan","year":"2021","unstructured":"Pan LN, Ma YF, Li Z, Hu JA, Xu ZH. KRAS G12V mutation upregulates PD-L1 expression via TGF-beta\/EMT-signaling pathway in human non-small cell lung cancer. Cell Biol Int. 2021;45:795\u2013803.","journal-title":"Cell Biol Int."},{"key":"16822_CR44","doi-asserted-by":"crossref","first-page":"101780","DOI":"10.1016\/j.redox.2020.101780","volume":"38","author":"C Glorieux","year":"2021","unstructured":"Glorieux C, Xia X, He YQ, et al. Regulation of PD-L1 expression in K-RAS-driven cancers through ROS-mediated FGFR1 signaling. Redox Biol. 2021;38:101780.","journal-title":"Redox Biol."},{"key":"16822_CR45","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217\u201323.","journal-title":"Nature."},{"key":"16822_CR46","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207\u201317.","journal-title":"N Engl J Med."},{"key":"16822_CR47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","volume":"23","author":"MG Fakih","year":"2022","unstructured":"Fakih MG, Kopetz S, Kuboki Y, et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 2022;23:115\u201324.","journal-title":"Lancet Oncol."},{"key":"16822_CR48","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1038\/s41467-021-22969-5","volume":"12","author":"KW Teng","year":"2021","unstructured":"Teng KW, Tsai ST, Hattori T, et al. Selective and noncovalent targeting of RAS mutants for inhibition and degradation. Nat Commun. 2021;12:2656.","journal-title":"Nat Commun."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16822-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16822-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16822-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T17:27:25Z","timestamp":1741195645000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16822-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["16822"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16822-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"20 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"DISCLOSURE"}}]}}